Lung adenocarcinoma patients with novel ALK fusion variants and their clinical responses to ALK inhibitors

Affiliations

Dafu Yang: The Second Department of Thoracic Medical Oncology The Second Hospital of Dalian Medical University Dalian Liaoning 116027 P. R. China
Dan Li: The Second Department of Thoracic Medical Oncology The Second Hospital of Dalian Medical University Dalian Liaoning 116027 P. R. China
Zhaoxia Dai: The Second Department of Thoracic Medical Oncology The Second Hospital of Dalian Medical University Dalian Liaoning 116027 P. R. China
Yutong Ma: Translational Medicine Research Institute Geneseeq Technology Inc Toronto Ontario M5G 1L7 Canada
Qiuxiang Ou: Translational Medicine Research Institute Geneseeq Technology Inc Toronto Ontario M5G 1L7 Canada
Xue Wu: Translational Medicine Research Institute Geneseeq Technology Inc Toronto Ontario M5G 1L7 Canada
Saiqiong Cui: The Second Department of Thoracic Medical Oncology The Second Hospital of Dalian Medical University Dalian Liaoning 116027 P. R. China

Abstract

No abstracts available.

ISSN: 2523-3548 (Online)
Publisher: Wiley
Country of publisher: Australia
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://onlinelibrary.wiley.com/journal/25233548